Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Glioma × mirdametinib × Clear all

Phase

Status

Not yet recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Neurofibromatosis 1 3 Neurofibromatoses 3 Neurofibroma, Plexiform 2 Neurofibroma 2 Melanoma 2 Colorectal Neoplasms 2 Breast Neoplasms 2 Vascular Malformations 1 Solid Tumor, Adult 1 Skin Diseases, Vascular 1 Primary Malignant Peripheral Nerve Sheath Tumors 1 Oligodendroglioma 1 Neurocytoma 1 Neoplasms, Neuroepithelial 1 NF1 1 Multiple Myeloma 1 Lymphatic Abnormalities 1 Lymphangioma, Cystic 1 Lymphangioma 1 Liposarcoma, Myxoid 1 Liposarcoma 1 Leukemia, Lymphocytic, Chronic, B-Cell 1 KRAS Mutant Non-Small Cell Lung Cancer 1 Glioma 1 Glioblastoma 1 Ganglioneuroma 1 Ganglioglioma 1 Colonic Neoplasms 1 Carcinoma, Non-Small-Cell Lung 1 Astrocytoma 1

Interventions

Temozolomide 158 Bevacizumab 68 Radiotherapy 67 Magnetic Resonance Spectroscopy 67 Irinotecan 31 Surgical Procedures, Operative 27 Radiation 24 Carboplatin 23 Specimen Handling 20 Carmustine 20 Nivolumab 19 Blood Specimen Collection 19 Aminolevulinic Acid 18 Biopsy 17 Lomustine 15 pembrolizumab 13 Radiotherapy, Intensity-Modulated 13 trametinib 12 X-Rays 12 Radiosurgery 12 Erlotinib Hydrochloride 12 Cyclophosphamide 12 fluorodopa F 18 11 Topotecan 11 Everolimus 11 Magnetic Resonance Imaging 10 IL13-PE38 10 dabrafenib 9 Etoposide 9 Drug Therapy 9

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT07521657 2026-04-13

NF118

University of Alabama at Birmingham

Phase 2 Not yet recruiting

Glioblastoma, Glioma, Neurofibromatosis 1

Data powered by HemOnc (CC BY 4.0) Colophon ⚡